1. Home
  2. ATYR vs CMCM Comparison

ATYR vs CMCM Comparison

Compare ATYR & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • CMCM
  • Stock Information
  • Founded
  • ATYR 2005
  • CMCM 2009
  • Country
  • ATYR United States
  • CMCM China
  • Employees
  • ATYR N/A
  • CMCM N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • ATYR Health Care
  • CMCM Technology
  • Exchange
  • ATYR Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • ATYR 126.3M
  • CMCM 115.6M
  • IPO Year
  • ATYR 2015
  • CMCM 2014
  • Fundamental
  • Price
  • ATYR $2.11
  • CMCM $4.64
  • Analyst Decision
  • ATYR Strong Buy
  • CMCM
  • Analyst Count
  • ATYR 4
  • CMCM 0
  • Target Price
  • ATYR $19.25
  • CMCM N/A
  • AVG Volume (30 Days)
  • ATYR 541.3K
  • CMCM 64.4K
  • Earning Date
  • ATYR 11-07-2024
  • CMCM 10-20-2024
  • Dividend Yield
  • ATYR N/A
  • CMCM N/A
  • EPS Growth
  • ATYR N/A
  • CMCM N/A
  • EPS
  • ATYR N/A
  • CMCM N/A
  • Revenue
  • ATYR $588,000.00
  • CMCM $97,678,928.00
  • Revenue This Year
  • ATYR N/A
  • CMCM N/A
  • Revenue Next Year
  • ATYR $2,057.88
  • CMCM N/A
  • P/E Ratio
  • ATYR N/A
  • CMCM N/A
  • Revenue Growth
  • ATYR N/A
  • CMCM N/A
  • 52 Week Low
  • ATYR $1.08
  • CMCM $1.64
  • 52 Week High
  • ATYR $2.50
  • CMCM $6.78
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 69.53
  • CMCM 57.09
  • Support Level
  • ATYR $1.83
  • CMCM $4.13
  • Resistance Level
  • ATYR $1.96
  • CMCM $5.68
  • Average True Range (ATR)
  • ATYR 0.09
  • CMCM 0.40
  • MACD
  • ATYR 0.03
  • CMCM 0.11
  • Stochastic Oscillator
  • ATYR 86.27
  • CMCM 53.36

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: